[Corrigendum] CD271+ stem cell treatment of patients with chronic stroke: A retrospective case series report
Affiliations: Bio‑Forum Foundation, 030121 Bucharest, Romania, Department of Radiology, Medical School, University of Crete, 71003 Heraklion, Greece, Department of Cardiothoracic Surgery, University General Hospital of Heraklion, 71003 Heraklion, Greece, Laboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Greece, Laboratory of Toxicology, Medical School, University of Crete, 71003 Heraklion, Greece, Cardiovascular Surgery Department, Angiomedica Hospital, 020657 Bucharest, Romania, CI Parhon Institute of Endocrinology, 011863 Bucharest, Romania
- Published online on: October 6, 2023 https://doi.org/10.3892/etm.2023.12243
- Article Number: 544
Copyright : © Stancioiu et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].
This article is mentioned in:
Exp Ther Med 20:[Related article:] 2055–2062, 2020; DOI: 10.3892/etm.2020.8948
Subsequently to the publication of the above paper, an interested reader expressed concerns as to the nature of the paper (what category of article the paper should have been assigned to), whether important information may have been missing from the article, and whether or not the work should have formed the basis a clinical trial.
In response, the authors have explained that this article was not conceived as a clinical study, but as a case series report, resulting from non-standardized administration of treatments to individual patients on a case-by-case basis (under the EU rules governing compassionate care and hospital exemption), not under homogenous inclusion/exclusion criteria applicable to a clinical study. Moreover, the ensuing patient data were analysed retrospectively, and the intent of the article was to provide insights into this type of treatment, for which further developments and improvements are still needed.
In consequence, the following changes are proposed for this article (the changed text is highlighted in bold):
i) as shown above, the title of the article has been changed to ‘CD271+ stem cell treatment of patients with chronic stroke: A retrospective case series report’, to reflect that this study should be regarded as a case series report;
ii) it should have been explicitly stated in the text that the patient data were analysed retrospectively, and that the intent of the article was to provide some preliminary insights into this type of treatment, which is still in need of further developments and improvements;
and iii) on p. 2061, the left-hand column, the first sentence in the final paragraph of the Discussion would have read better as follows: ‘Based on above data and the cited literature on mesenchymal stem cells - of which CD271+ represent a subpopulation - it can be said that treating chronic stroke patients with CD271+ stem cells administered intrathecally and/or intravenously is a safe therapeutic option with good results especially for spasticity and aphasia; at the same time it needs to be further studied and improved...’.
These oversights did not have an impact on the conclusions reported in this study, and all the authors agree to the publication of this Corrigendum.